Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q1 FY25 Earnings Presentation
21 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Aug 24, 2024
Slide 1: Exchange disclosure letter under Regulation 30
Ref: Akums/Exchange/2024-25/08 August 24, 2024 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Bandra Kurla Complex, Jeejeebhoy Towers, Dalal Street, Bandra (E),Mumbai – 400 051 Fort, Mumba
Slide 2: Investor Presentation August 2024
Investor Presentation August 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Akums Drugs and Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscr
Slide 4: Managing Directors' Message
Managing Directors’ Message It gives us immense pleasure to announce our first quarterly results as a publically listed company. The company got listed on respective stock exchanges on August 6th 2024, a momentous day for each one of us. We wish to extend our sincere gratitude to all shareholders, s
Slide 5: Q1 FY24-25 Financial Performance Highlights
Q1 FY24-25 Financial Performance Highlights
Slide 6: Key Highlights – June 2024
Key Highlights – June 2024 Adjusted EBITDA* grew from Rs. 1,080 mn (11.0%) to Rs. 1,307 mn (12.7%) while gross Adjusted PAT** increased from Rs. 377 mn margins improved by Rs. 468 mn from Rs. 3,763 (3.9%) to Rs. 573 mn (5.6%) YoY basis mn (38.8%) to Rs. 4,231 mn (41.5%) on YoY basis Cash flow from o
Slide 7: Consolidated Quarterly Performance Highlights
Consolidated Quarterly Performance Highlights (1) Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance cost + depreciation and amortization (2) Adjusted PAT = PAT + Fair value changes to financial instrument, (3) Adjusted Equity = Equity attributable to equity h
Slide 8: Segmental Financials
Segmental Financials CDMO Branded and Generic Formulations API Margin % 14.4% 15.5% Margin % 3.9% 10.2% Margin % -23.0% -17.4% 5.6% 12.5% 82.6% 7,820 697 7,405 1,913 1,674 382 1,068 1,212 74 171 Reven u e EBITDA -88 -122 Reven u e EBITDA Reven u e EBITDA Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY
Slide 9: IPO proceeds utilization plan
IPO proceeds utilization plan The Company successfully got listed on 6 August 2024. Post listing, the Company received Rs. 6,373.70 million (net of offer expenses borne by Company) to be spent as mentioned. Purpose of Funds Amount (in million) Loan repayment Akums 1,599.10 Subsidiaries 2,270.90 Gene
Slide 10: Key Performance Indicators (KPIs)
Key Performance Indicators (KPIs) Quarter ended Year ended S. No. Financial KPIs Unit 30-Jun-24 31-Mar-24 30-Jun-23 31-Mar-24 (a) Revenue from operations (₹ in million) 10,191.13 9,442.09 9,698.86 41,781.82 (b) EBITDA(1) (₹ in million) 1,345.63 132.30 -1,171.75 1,570.10 (c) EBITDA margin(2) % 13.12%
Slide 11: Key Performance Indicators (cont'd)
Key Performance Indicators (cont’d) Notes: (1) EBITDA refers to sum of EBIT and depreciation and amortization expense. (2) EBITDA margin is calculated as EBITDA divided by total income. (3) EBIT refers to earnings before interest and tax, calculated as the sum of restated profit/(loss) before share
Slide 12: Growth plan in Jammu
Growth plan in Jammu • Plan to set up greenfield manufacturing units in the UT of Jammu and Kashmir Expansion Plan • Two manufacturing units will be set up – one multi-dosage facility focusing on pharmaceuticals and other dedicated unit to nutraceuticals • Under the Govt. of India’s New Central Sect
Slide 13: India's Largest India-Focused CDMO Player
Akums has a strategic presence across the pharmaceutical value chain driven by large R&D and manufacturing capabilities which reflects in the diverse and longstanding client relationships. 4,959 Cr 4,146 1,524 220+ (49.6bn) units Commercialized Customers; serving Innovative formulations across 26 ou
Slide 14: Two Decades' Legacy of Expertise, Experience and Trust
Two Decades’ Legacy of Expertise, Experience and Trust 2004–2010 2010–2021 2021 – 2024 Build Strengthen Accelerate Incorporated in April 2004 Dedicated facilities for Hormones, In Nov 2019, Quadria Capital(3) Set up of first plant for oral Cosmetics and Dermatology bought a minority stake (1
Slide 15: Akums has a right to win in a large pharma opportunity
Akums has a right to win in a large pharma opportunity 1 Largest India Focused CDMO with diverse client base 2 Comprehensive Offerings With Advanced Manufacturing Capabilities 3 Large and Growing R&D Capabilities Across Product Portfolio 4 Strategic Presence Across the Pharmaceutical Value Chain 5 E
Slide 16: Largest India Focused CDMO with diverse client base
1 Largest India Focused CDMO1 with diverse client base 10.0% share by value in 30.2% share in Indian 18,500+ 4,000+ 60+ total addressable Indian Domestic CDMO market SKUs manufactured in Formulations Dosage Forms domestic CDMO in FY242 in FY24 by value2 FY24 Signifcant nase of CDMO Clients… .. with
Slide 17: Technologically Advanced Manufacturing Capabilities
2 Technologically Advanced Manufacturing Capabilities Annual Capacity Location Year Dosage Forms Key Accreditations1 (Cr units) 1 Haridwar 2004 649 Oral Solids 2 Haridwar 2007 15 Oral Liquids 3 Haridwar 2007 39 Sterile Preparations 4 Hormonal – Oral, Injectables and Haridwar 2010 244 Topicals 5 Hari
Slide 18: Extensive R&D Capabilities Across Product Portfolio
3 Extensive R&D Capabilities Across Product Portfolio R&D Capabilities Innovative In-house Technologies 4 R&D Centers across formulations and API, 2 DSIR approved1 R&D scientists with 300+ doctorates 406 and post-graduates1 925 DCGI approvals1, along with + 923 FSSAI approvals Patent applications fi
Slide 19: Strategic Presence Across the Pharmaceutical Value Chain
4 Strategic Presence Across the Pharmaceutical Value Chain In addition to the CDMO Business, Akums is also engaged in manufacturing and sale of Branded Formulations, Trade Generics and APIs across domestic and overseas market Domestic Branded Formulations Exports Oriented Branded Formulations Dossie
Slide 20: Experienced Board Directors of Board
5 Experienced Board Directors of Board Sanjeev Jain Sandeep Jain Sanjay Sinha Sunil Kumar Thakur Managing Director Managing Director Whole Time Director Non-Executive Director • Co-founder and promoter • Co-founder and promoter • Over 4 decades of experience in • Partner at Quadria Capital and co- •
Slide 21: Slide 21
Akums Drugs and Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix